![Approvals of antibody-based therapies have accelerated sharply since 2000 with oncology dominating the landscape, newer modalities like ADCs and bispecifics gaining momentum [2]](https://european-biotechnology.com/wp-content/uploads/2025/10/Seite-71_EB325_Indivumed_Grafik1_RZ_X3-180x180.png)
Indivumed GmbHFifty years after the invention of hybridoma technology, biologics have become a cornerstone of oncology drug discovery and development. From the first monoclonal antibody approval in 1995 to today’s complex antibody formats and cell-based therapies, biologics are reshaping cancer drug discovery. Yet, despite remarkable progress, the urgent need for novel targets that can exploit recent technological developments remains high.
Tag Archive for: Indivumed GmbH
Indivumed GmbHThe Hamburg-based company Indivumed has repositioned itself, sending a clear message with a recent change in leadership: A new chapter is beginning with the focus on discovering and developing novel therapeutic targets for innovative cancer therapies. |transkript spoke with Prof. Dr. Hartmut Juhl and Dr. Matthias Evers.